In this interview with Eli Roth, the acclaimed director talks about putting together the 'Red Light Disco' compilation with ...
Eli Roth Launches The Horror Section Production Studio, Invites Fans to Become Investors (Exclusive)
By Borys Kit Senior Film Writer There will be blood. And probably lots of it. Filmmaker Eli Roth has launched The Horror Section, a new, all-encompassing horror media company that aims not just to ...
Eli Manning has more game than just being a quarterback. The former New York Giants star took on women's basketball icon Caitlin Clark in Pop-A-Shot and downed the Indiana Fever star. The players ...
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...
The Iowa women's basketball legend and reigning WNBA Rookie of the Year for the Indiana Fever made a guest appearance on "The Eli Manning Show" on YouTube, playing the former New York Giants ...
The image of Israeli hostage Eli Sharabi being released from Gaza a little over two weeks ago, looking gaunt and weak, shocked and angered Israel and leaders around the world. His brother Sharon ...
Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch ...
Broadcast coverage will be available on the league's YouTube channel. "Here's what I don't want people to do. If anyone wants to watch Eli Ellis, he plays in the OTE and sometimes those games ...
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...
New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results